Sakurada Y, et al. - This trial encompassed an inspection of the factors linked to visual improvement and retreatment, 12 months after a combination therapy of intravitreal injection of ranibizumab or aflibercept, followed by photodynamic therapy for polypoidal choroidal vasculopathy. The findings displayed a favourable visual outcome at 12 months, in eyes treated by photodynamic therapy combined with intravitreal ranibizumab or aflibercept, regardless of the therapeutic modalities. A connection was brought to light between the baseline greater subfoveal choroidal thickness with a better visual outcome and with a reduction in the need for retreatment.